Evidence map›Paper›PMID 33299675›Full record

ReviewNeurology. Clinical practice2020

Clinical neuro-oncology for the neurologist.

Rimas V Lukas, Jennie W Taylor, Sylvia C Kurz, Nimish A Mohile

Abstract readReview
In one paragraph

Review in Neurology. Clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rimas V LukasDepartment of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY.ORCID 0000-0003-4115-6370
Jennie W TaylorDepartment of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY.
Sylvia C KurzDepartment of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY.
Nimish A MohileDepartment of Neurology (RVL), Northwestern University, Chicago, IL; The Lou & Jean Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center (RVL), Chicago, IL; Departments of Neurology and Neurological Surgery (JWT), University of California-San Francisco; Department of Neurology (SCK), New York University, New York; Brain and Spine Tumor Center at the Perlmutter Cancer Center (SCK), New York, NY; and Department of Neurology (NAM), University of Rochester, NY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewNeuro-oncologic patients are routinely encountered in clinical practice. Neuro-oncology is a rapidly evolving field, so understanding the most classic paradigms and contemporary advances will optimize patient care. RECENT

findingsWe discuss the recent reclassification of tumors via molecular characteristics as it applies to direct clinical practice and review the contemporary standard of care for infiltrating gliomas, meningiomas, brain metastases, and CNS lymphoma. SUMMARY: We provide a straightforward primer on neuro-oncology with a focus on the brain tumors most commonly encountered by the adult neurologist and a clear emphasis on clinically relevant points including those which have recently become incorporated into our standard management. We cite key reviews to allow interested readers an opportunity to gain a more comprehensive understanding of specific topics.

Identifiers

PMID33299675
PMCPMC7717629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.